
Merck’s Phase 3 KEYNOTE-B96 Trial Meets PFS Goal in Platinum-Resistant Ovarian Cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today reported that its Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) has met its primary endpoint, showing a statistically significant…












